Novartis (NVS) Said in Talks to Buy Amneal Pharma - Bloomberg

November 14, 2016 7:21 AM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Novartis (NYSE: NVS) is in talks to acquire generic-drugs maker Amneal Pharmaceuticals, according to Bloomberg, citing people familiar with the matter. The company could be valued at as much as $8 billion.

Amneal is working with an adviser and an agreement could be reached soon.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Mergers and Acquisitions, Rumors

Related Entities

Definitive Agreement

Add Your Comment